Market Challenges And Opportunities

Global Poultry Diagnostics Market – Drivers

Increasing adoption of inorganic growth strategies such as product launches by key market players

Increasing adoption of inorganic growth strategies such as product launches by key market players is expected to drive the global poultry diagnostics market growth over the forecast period. For instance, in April 2022, BIOMERIEUX, a biotechnology company, announced that they had launched GENE-UP QUANT Salmonella, true non-enrichment quantification diagnostic for Salmonella. The exact quantification and fast turnaround time of the new test allows poultry producers to evaluate and improve operational processes and mitigation measures, while reducing antimicrobial use, cost and waste.

Global Poultry Diagnostics Market: Restraint

Lack of awareness of poultry diseases is expected to hinder the global poultry diagnostics market over the forecast period. For instance, in August 2020, according to the data published in frontiers journal, emergence of poultry diseases due to improper nutrition and unsuitable environment affects the development and structure of the poultry farming.

Global Poultry Diagnostics Market – Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe, and the World Health Organization declared it a public health emergency on January 30, 2020.

COVID-19 can affect the economy in three main ways: by directly affecting the production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries such as China, India, Saudi Arabia, the U.A.E., Egypt, and others are facing problems with the transportation of drugs from one place to another.

However, the COVID-19 pandemic had a positive impact on the global poultry diagnostics market. For instance, in June 2020, Transasia Bio-Medicals, a diagnostic company, announced that they had received an approval from The Indian Council of Medical Research (ICMR) for ELISA antibody IgG testing kit for Covid-19 and transferred the technology to Zydus Pharmaceuticals, Inc., a pharmaceutical company, for the mass production of kits.